Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Sell
41
ROIV Quote, Financials, Valuation and Earnings
Last price:
$22.53
Seasonality move
:
-10.09%
Day range:
$22.47 - $23.11
52-week range:
$8.73 - $23.91
Dividend yield:
0%
P/E ratio:
1.91x
P/S ratio:
773.36x
P/B ratio:
3.59x
Volume:
3.5M
Avg. volume:
7.2M
1-year change:
102.24%
Market cap:
$15.7B
Revenue:
$29.1M
EPS (TTM):
-$0.55
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ROIV
Roivant Sciences Ltd.
|
$6.1M | -$0.31 | -31.92% | -2.85% | $27.00 |
|
AUTL
Autolus Therapeutics Plc
|
$24.1M | -$0.41 | 199.85% | -6.42% | $9.30 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
IMVT
Immunovant, Inc.
|
-- | -$0.70 | -- | -10.01% | $40.31 |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$197.1M | $0.38 | 48.37% | -62.86% | $55.00 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ROIV
Roivant Sciences Ltd.
|
$22.53 | $27.00 | $15.7B | 1.91x | $0.00 | 0% | 773.36x |
|
AUTL
Autolus Therapeutics Plc
|
$1.42 | $9.30 | $377.9M | -- | $0.00 | 0% | 7.37x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.16 | $17.94 | $1.8M | -- | $0.00 | 0% | 0.73x |
|
IMVT
Immunovant, Inc.
|
$26.83 | $40.31 | $4.7B | -- | $0.00 | 0% | -- |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$44.64 | $55.00 | $3.4B | 99.58x | $0.00 | 0% | 5.72x |
|
NCNA
NuCana Plc
|
$2.95 | $104.00 | $12.3M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ROIV
Roivant Sciences Ltd.
|
2.22% | 0.698 | 0.91% | 32.78x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 2.916 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.608 | -- | 1.20x |
|
IMVT
Immunovant, Inc.
|
-- | 1.621 | -- | 8.28x |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
1.78% | -0.723 | 0.33% | 3.27x |
|
NCNA
NuCana Plc
|
0.52% | -0.467 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ROIV
Roivant Sciences Ltd.
|
$539K | -$306.2M | -17.09% | -17.38% | -19492.87% | -$193.5M |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
IMVT
Immunovant, Inc.
|
-$105K | -$131.8M | -88.09% | -88.1% | -- | -$102.5M |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$97.3M | $24M | 7.44% | 7.6% | 13.28% | $33M |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
Roivant Sciences Ltd. vs. Competitors
-
Which has Higher Returns ROIV or AUTL?
Autolus Therapeutics Plc has a net margin of -10569% compared to Roivant Sciences Ltd.'s net margin of -373.3%. Roivant Sciences Ltd.'s return on equity of -17.38% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital ROIVRoivant Sciences Ltd.34.31% -$0.17 $4.9B AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About ROIV or AUTL?
Roivant Sciences Ltd. has a consensus price target of $27.00, signalling upside risk potential of 19.84%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.30 which suggests that it could grow by 554.93%. Given that Autolus Therapeutics Plc has higher upside potential than Roivant Sciences Ltd., analysts believe Autolus Therapeutics Plc is more attractive than Roivant Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ROIVRoivant Sciences Ltd.9 1 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is ROIV or AUTL More Risky?
Roivant Sciences Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.012, suggesting its more volatile than the S&P 500 by 101.185%.
-
Which is a Better Dividend Stock ROIV or AUTL?
Roivant Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences Ltd. pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ROIV or AUTL?
Roivant Sciences Ltd. quarterly revenues are $1.6M, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Roivant Sciences Ltd.'s net income of -$166M is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Roivant Sciences Ltd.'s price-to-earnings ratio is 1.91x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences Ltd. is 773.36x versus 7.37x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ROIVRoivant Sciences Ltd.773.36x 1.91x $1.6M -$166M AUTLAutolus Therapeutics Plc7.37x -- $21.1M -$78.6M
-
Which has Higher Returns ROIV or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -10569% compared to Roivant Sciences Ltd.'s net margin of --. Roivant Sciences Ltd.'s return on equity of -17.38% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital ROIVRoivant Sciences Ltd.34.31% -$0.17 $4.9B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About ROIV or BDRX?
Roivant Sciences Ltd. has a consensus price target of $27.00, signalling upside risk potential of 19.84%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 8133.86%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Roivant Sciences Ltd., analysts believe Biodexa Pharmaceuticals Plc is more attractive than Roivant Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ROIVRoivant Sciences Ltd.9 1 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is ROIV or BDRX More Risky?
Roivant Sciences Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.952, suggesting its less volatile than the S&P 500 by 4.8%.
-
Which is a Better Dividend Stock ROIV or BDRX?
Roivant Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences Ltd. pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ROIV or BDRX?
Roivant Sciences Ltd. quarterly revenues are $1.6M, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Roivant Sciences Ltd.'s net income of -$166M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Roivant Sciences Ltd.'s price-to-earnings ratio is 1.91x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences Ltd. is 773.36x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ROIVRoivant Sciences Ltd.773.36x 1.91x $1.6M -$166M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns ROIV or IMVT?
Immunovant, Inc. has a net margin of -10569% compared to Roivant Sciences Ltd.'s net margin of --. Roivant Sciences Ltd.'s return on equity of -17.38% beat Immunovant, Inc.'s return on equity of -88.1%.
Company Gross Margin Earnings Per Share Invested Capital ROIVRoivant Sciences Ltd.34.31% -$0.17 $4.9B IMVTImmunovant, Inc.-- -$0.73 $519.7M -
What do Analysts Say About ROIV or IMVT?
Roivant Sciences Ltd. has a consensus price target of $27.00, signalling upside risk potential of 19.84%. On the other hand Immunovant, Inc. has an analysts' consensus of $40.31 which suggests that it could grow by 50.25%. Given that Immunovant, Inc. has higher upside potential than Roivant Sciences Ltd., analysts believe Immunovant, Inc. is more attractive than Roivant Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ROIVRoivant Sciences Ltd.9 1 0 IMVTImmunovant, Inc.11 4 0 -
Is ROIV or IMVT More Risky?
Roivant Sciences Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immunovant, Inc. has a beta of 0.572, suggesting its less volatile than the S&P 500 by 42.758%.
-
Which is a Better Dividend Stock ROIV or IMVT?
Roivant Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immunovant, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences Ltd. pays -- of its earnings as a dividend. Immunovant, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ROIV or IMVT?
Roivant Sciences Ltd. quarterly revenues are $1.6M, which are larger than Immunovant, Inc. quarterly revenues of --. Roivant Sciences Ltd.'s net income of -$166M is lower than Immunovant, Inc.'s net income of -$126.5M. Notably, Roivant Sciences Ltd.'s price-to-earnings ratio is 1.91x while Immunovant, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences Ltd. is 773.36x versus -- for Immunovant, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ROIVRoivant Sciences Ltd.773.36x 1.91x $1.6M -$166M IMVTImmunovant, Inc.-- -- -- -$126.5M
-
Which has Higher Returns ROIV or KNSA?
Kiniksa Pharmaceuticals International Plc has a net margin of -10569% compared to Roivant Sciences Ltd.'s net margin of 10.19%. Roivant Sciences Ltd.'s return on equity of -17.38% beat Kiniksa Pharmaceuticals International Plc's return on equity of 7.6%.
Company Gross Margin Earnings Per Share Invested Capital ROIVRoivant Sciences Ltd.34.31% -$0.17 $4.9B KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M -
What do Analysts Say About ROIV or KNSA?
Roivant Sciences Ltd. has a consensus price target of $27.00, signalling upside risk potential of 19.84%. On the other hand Kiniksa Pharmaceuticals International Plc has an analysts' consensus of $55.00 which suggests that it could grow by 23.21%. Given that Kiniksa Pharmaceuticals International Plc has higher upside potential than Roivant Sciences Ltd., analysts believe Kiniksa Pharmaceuticals International Plc is more attractive than Roivant Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ROIVRoivant Sciences Ltd.9 1 0 KNSAKiniksa Pharmaceuticals International Plc6 0 0 -
Is ROIV or KNSA More Risky?
Roivant Sciences Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kiniksa Pharmaceuticals International Plc has a beta of 0.040, suggesting its less volatile than the S&P 500 by 95.991%.
-
Which is a Better Dividend Stock ROIV or KNSA?
Roivant Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiniksa Pharmaceuticals International Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences Ltd. pays -- of its earnings as a dividend. Kiniksa Pharmaceuticals International Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ROIV or KNSA?
Roivant Sciences Ltd. quarterly revenues are $1.6M, which are smaller than Kiniksa Pharmaceuticals International Plc quarterly revenues of $180.9M. Roivant Sciences Ltd.'s net income of -$166M is lower than Kiniksa Pharmaceuticals International Plc's net income of $18.4M. Notably, Roivant Sciences Ltd.'s price-to-earnings ratio is 1.91x while Kiniksa Pharmaceuticals International Plc's PE ratio is 99.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences Ltd. is 773.36x versus 5.72x for Kiniksa Pharmaceuticals International Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ROIVRoivant Sciences Ltd.773.36x 1.91x $1.6M -$166M KNSAKiniksa Pharmaceuticals International Plc5.72x 99.58x $180.9M $18.4M
-
Which has Higher Returns ROIV or NCNA?
NuCana Plc has a net margin of -10569% compared to Roivant Sciences Ltd.'s net margin of --. Roivant Sciences Ltd.'s return on equity of -17.38% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital ROIVRoivant Sciences Ltd.34.31% -$0.17 $4.9B NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About ROIV or NCNA?
Roivant Sciences Ltd. has a consensus price target of $27.00, signalling upside risk potential of 19.84%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 704984.75%. Given that NuCana Plc has higher upside potential than Roivant Sciences Ltd., analysts believe NuCana Plc is more attractive than Roivant Sciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ROIVRoivant Sciences Ltd.9 1 0 NCNANuCana Plc0 1 0 -
Is ROIV or NCNA More Risky?
Roivant Sciences Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.248%.
-
Which is a Better Dividend Stock ROIV or NCNA?
Roivant Sciences Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roivant Sciences Ltd. pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ROIV or NCNA?
Roivant Sciences Ltd. quarterly revenues are $1.6M, which are larger than NuCana Plc quarterly revenues of --. Roivant Sciences Ltd.'s net income of -$166M is lower than NuCana Plc's net income of -$378.9K. Notably, Roivant Sciences Ltd.'s price-to-earnings ratio is 1.91x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roivant Sciences Ltd. is 773.36x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ROIVRoivant Sciences Ltd.773.36x 1.91x $1.6M -$166M NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 42x
Alerts
Sell
44
SANM alert for Jan 28
Sanmina Corp. [SANM] is up 6.66% over the past day.
Sell
16
HUM alert for Jan 28
Humana, Inc. [HUM] is down 4.24% over the past day.
Sell
21
AGYS alert for Jan 28
Agilysys, Inc. [AGYS] is down 3.3% over the past day.
